385 related articles for article (PubMed ID: 22387005)
41. The ALDH1⁺ subpopulation of the human NMFH-1 cell line exhibits cancer stem-like characteristics.
Li D; Zhang T; Gu W; Li P; Cheng X; Tong T; Wang W
Oncol Rep; 2015 May; 33(5):2291-8. PubMed ID: 25760144
[TBL] [Abstract][Full Text] [Related]
42. ALDH1 is a prognostic factor for patients treated with neoadjuvant chemoradiotherapy and radical resection for stage III rectal cancer.
Oh SY; Sohn SH; Yim H; Lee D; Suh KW; Kim YB
J Surg Oncol; 2015 Feb; 111(2):243-7. PubMed ID: 25270363
[TBL] [Abstract][Full Text] [Related]
43. The prognostic significance of proliferative indices in surgically resected IIIA-N2 non-small cell lung cancer after induction chemotherapy.
Corzani R; Luzzi L; Spina D; Voltolini L; Paladini P; Ghiribelli C; Ghisalberti M; Borrelli R; Meniconi F; Monaci N; Gotti G
J Cardiovasc Surg (Torino); 2017 Oct; 58(5):763-769. PubMed ID: 24740119
[TBL] [Abstract][Full Text] [Related]
44. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer.
Tirino V; Camerlingo R; Franco R; Malanga D; La Rocca A; Viglietto G; Rocco G; Pirozzi G
Eur J Cardiothorac Surg; 2009 Sep; 36(3):446-53. PubMed ID: 19464919
[TBL] [Abstract][Full Text] [Related]
45. Lusianthridin targeting of lung cancer stem cells via Src-STAT3 suppression.
Bhummaphan N; Petpiroon N; Prakhongcheep O; Sritularak B; Chanvorachote P
Phytomedicine; 2019 Sep; 62():152932. PubMed ID: 31100681
[TBL] [Abstract][Full Text] [Related]
46. CXCR4 is involved in CD133-induced EMT in non-small cell lung cancer.
Tu Z; Xie S; Xiong M; Liu Y; Yang X; Tembo KM; Huang J; Hu W; Huang X; Pan S; Liu P; Altaf E; Kang G; Xiong J; Zhang Q
Int J Oncol; 2017 Feb; 50(2):505-514. PubMed ID: 28000861
[TBL] [Abstract][Full Text] [Related]
47. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
[TBL] [Abstract][Full Text] [Related]
48. TWIST1 and SNAI1 as markers of poor prognosis in human colorectal cancer are associated with the expression of ALDH1 and TGF-β1.
Kim YH; Kim G; Kwon CI; Kim JW; Park PW; Hahm KB
Oncol Rep; 2014 Mar; 31(3):1380-8. PubMed ID: 24402192
[TBL] [Abstract][Full Text] [Related]
49. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
50. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.
Salnikov AV; Gladkich J; Moldenhauer G; Volm M; Mattern J; Herr I
Int J Cancer; 2010 Feb; 126(4):950-8. PubMed ID: 19676044
[TBL] [Abstract][Full Text] [Related]
51. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M; Rocha RM; Soares FA; Gobbi H
Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
[TBL] [Abstract][Full Text] [Related]
52. Differential characteristics of CD133(+) and CD133 (-) Jurkat cells.
Anbarlou A; Atashi A; Soleimani M; AkhavanRahnama M; Bohloli M; Mossahebi-Mohammadi M
In Vitro Cell Dev Biol Anim; 2015 Jun; 51(6):556-61. PubMed ID: 25630537
[TBL] [Abstract][Full Text] [Related]
53. Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer.
Pirozzi G; Tirino V; Camerlingo R; La Rocca A; Martucci N; Scognamiglio G; Franco R; Cantile M; Normanno N; Rocco G
Oncol Rep; 2013 May; 29(5):1763-8. PubMed ID: 23426441
[TBL] [Abstract][Full Text] [Related]
54. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K
Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363
[TBL] [Abstract][Full Text] [Related]
55. Expression of CD133 and CD117 in 64 Serous Ovarian Cancer Cases.
Stemberger-Papić S; Vrdoljak-Mozetic D; Ostojić DV; Rubesa-Mihaljević R; Krigtofić I; Brncić-Fisher A; Kragević M; Eminović S
Coll Antropol; 2015 Sep; 39(3):745-53. PubMed ID: 26898076
[TBL] [Abstract][Full Text] [Related]
56. Biologic characteristics of the side population of human small cell lung cancer cell line H446.
Wang B; Yang H; Huang YZ; Yan RH; Liu FJ; Zhang JN
Chin J Cancer; 2010 Mar; 29(3):254-60. PubMed ID: 20193106
[TBL] [Abstract][Full Text] [Related]
57. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
Alberti L; Losi L; Leyvraz S; Benhattar J
PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
[TBL] [Abstract][Full Text] [Related]
58. Reduced SLC27A2 induces cisplatin resistance in lung cancer stem cells by negatively regulating Bmi1-ABCG2 signaling.
Su J; Wu S; Tang W; Qian H; Zhou H; Guo T
Mol Carcinog; 2016 Nov; 55(11):1822-1832. PubMed ID: 26513225
[TBL] [Abstract][Full Text] [Related]
59. Activated leukocyte cell adhesion molecule (CD166): an "inert" cancer stem cell marker for non-small cell lung cancer?
Tachezy M; Zander H; Wolters-Eisfeld G; Müller J; Wicklein D; Gebauer F; Izbicki JR; Bockhorn M
Stem Cells; 2014 Jun; 32(6):1429-36. PubMed ID: 24501004
[TBL] [Abstract][Full Text] [Related]
60. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
Kobayashi I; Takahashi F; Nurwidya F; Nara T; Hashimoto M; Murakami A; Yagishita S; Tajima K; Hidayat M; Shimada N; Suina K; Yoshioka Y; Sasaki S; Moriyama M; Moriyama H; Takahashi K
Biochem Biophys Res Commun; 2016 Apr; 473(1):125-132. PubMed ID: 26996130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]